These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5008235)

  • 1. Synthesis of three oxytocin analogs related to (1-deaminopenicillamine)oxytocin possessing antioxytocic acitvity.
    Vavrek RJ; Ferger MF; Allen GA; Rich DH; Blomquist AT; Du Vigneaud V
    J Med Chem; 1972 Feb; 15(2):123-6. PubMed ID: 5008235
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis of (1-(L-2-hydroxy-3-mercaptopropanoic acid))oxytocin, a highly potent analogue of oxytocin.
    Wälti M; Hope DB
    J Chem Soc Perkin 1; 1972; 15():1946-50. PubMed ID: 4672381
    [No Abstract]   [Full Text] [Related]  

  • 3. [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin.
    Nestor JJ; Ferger MF; du Vigneaud V
    J Med Chem; 1975 Mar; 18(3):284-7. PubMed ID: 1133819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of (1-(D-2-hydroxy-3-mercaptopropanoic acid))oxytocin, a diastereoisomer of the hydroxy-isostere of oxytocin.
    Wälti M; Hope DB
    J Chem Soc Perkin 1; 1974; 2():202-5. PubMed ID: 4856211
    [No Abstract]   [Full Text] [Related]  

  • 5. (1-beta-mercapto-beta,beta-diethylpropionic acid,4-leucine)-8-lysine-vasopressin and (1-beta-mercapto-beta,beta-diethylpropionic acid,4-leucine)oxytocin, compounds possessing antihormonal properties.
    Dyckes DF; Nestor JJ; Ferger MF; Du Vigneaud V; Chan WY
    J Med Chem; 1974 Sep; 17(9):969-72. PubMed ID: 4855467
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response of oxytocin.
    Schulz H; Du Vigneaud V
    J Med Chem; 1966 Sep; 9(5):647-50. PubMed ID: 5969030
    [No Abstract]   [Full Text] [Related]  

  • 7. Further studies of the role of the asparagine residue in oxytocin. Synthesis and biological properties of (5- , -diaminobutyric acid)oxytocin.
    Hase S; Schwartz IL; Walter R
    J Med Chem; 1972 Feb; 15(2):126-8. PubMed ID: 5008236
    [No Abstract]   [Full Text] [Related]  

  • 8. Some pharmacologic studies on 1-L-penicillamine-oxytocin and 1-deaminopenicillamine-oxytocin: two potent oxytocin inhibitors.
    Chan WY; Fear R; Du Vigneaud V
    Endocrinology; 1967 Dec; 81(6):1267-77. PubMed ID: 6064990
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of an amide group in place of the disulfide bridge in deamino-oxytocin.
    Hase S; Sakakibara S; Wahrenburg M; Walter R
    J Med Chem; 1972 Oct; 15(10):1017-9. PubMed ID: 4672192
    [No Abstract]   [Full Text] [Related]  

  • 10. (1-Beta-mercaptopropionic acid, 2-(3,5-dibromo-L-tyrosine))oxytocin, a potent inhibitor of oxytocin.
    Lundell EO; Ferger MF
    J Med Chem; 1975 Oct; 18(10):1045-7. PubMed ID: 1159688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and pharmacological properties of [1-L-penicillamine,4-L-leucine]oxytocin.
    Ferger MF; Chan WY
    J Med Chem; 1975 Oct; 18(10):1020-2. PubMed ID: 1159679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin).
    Manning M; Lowbridge J; Sawyer WH; Haldar J
    J Med Chem; 1976 Mar; 19(3):376-80. PubMed ID: 943546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of 1-L-penicillamine-oxytocin and 1-deaminopenicillamine-oxytocin to inhibit the uterine effect of oxytocin in rabbits in vivo.
    Fuchs AR; Lopes AC
    Endocrinology; 1970 Jan; 86(1):71-6. PubMed ID: 5409455
    [No Abstract]   [Full Text] [Related]  

  • 14. Study of pituitary hormone analogs for their inhibitory properties and resistance to carboxamidopeptidases: (9-L-proline)oxytocin, (9-L-glutamic acid)oxytocin, and (8-L-lysine,9-glycine methylamide)oxytocin.
    Grzonka Z; Glass JD; Schwartz IL; Walter R
    J Med Chem; 1974 Dec; 17(12):1294-8. PubMed ID: 4427327
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and some pharmacological properties of (1-deamino,9-thioglycine)oxytocin.
    Jones WC; Nestor JJ; Du Vigneaud V
    J Am Chem Soc; 1973 Aug; 95(17):5677-9. PubMed ID: 4733810
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis and some pharmacological properties of 6-L-penicillamine-oxytocin.
    Schulz H; du Vigneaud V
    J Med Chem; 1967 Nov; 10(6):1037-9. PubMed ID: 6056028
    [No Abstract]   [Full Text] [Related]  

  • 17. Solid phase synthesis of (3,4-dileucine)-oxytocin and a study of some of its pharmacological properties.
    Wille MA; Cahn WY; Du Vigneaud V
    J Med Chem; 1972 Jan; 15(1):11-2. PubMed ID: 5061981
    [No Abstract]   [Full Text] [Related]  

  • 18. Substrate requirements for the oxytocin-induced motility of isolated rat uterus.
    Goldraij A; Gimeno AL; De Gimeno MF
    Acta Physiol Lat Am; 1973; 23(2):113-23. PubMed ID: 4795841
    [No Abstract]   [Full Text] [Related]  

  • 19. The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.
    Sawyer WH; Haldar J; Gazis D; Seto J; Bankowski K; Lowbridge J; Turan A; Manning M
    Endocrinology; 1980 Jan; 106(1):81-91. PubMed ID: 7349976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of magnesium ion and oxytocin inhibitors on the uterotonic activity of oxytocin and prostaglandins E2 and F2ALPHA.
    Chan WY; Hruby VJ; Du Vigneaud V
    J Pharmacol Exp Ther; 1974 Jul; 190(1):77-87. PubMed ID: 4847314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.